Impact of Hyperglycemia and Age on Outcomes in Patients With Acute Myeloid Leukemia

Susan Storey, PhD, RN, AOCNS®, and Diane Von Ah, PhD, RN, FAAN

Storey is a visiting assistant scientist and Von Ah is an associate professor and chair of the Department of Community and Health Systems, both in the School of Nursing at Indiana University in Indianapolis.

This research was funded, in part, by Sigma Theta Tau International, Alpha Chapter, and the St. Vincent Foundation. Mention of specific products and opinions related to those products do not indicate or imply endorsement by the Oncology Nursing Forum or the Oncology Nursing Society.

Storey and Von Ah contributed to the conceptualization and design and the manuscript preparation. Storey completed the data collection and provided the statistical support and analysis.

Storey can be reached at sustorey@iu.edu, with copy to editor at ONFEditor@ons.org.

Submitted September 2015. Accepted for publication October 28, 2015.

Key words: acute myeloid leukemia; hyperglycemia; health outcomes; infection; neutropenic days; hospital length of stay

ONF, 43(5), 595-601.

doi: 10.1188/16.0NF.595-601

Purpose/Objectives: To examine the prevalence and impact of hyperglycemia on health outcomes (number of neutropenic days, infection, and hospital length of stay) in patients hospitalized for acute myeloid leukemia (AML) receiving initial induction therapy.

Design: Retrospective, descriptive study.

Setting: A large urban hospital in Indianapolis, IN.

Sample: 103 patients with AML and a subset of 41 patients aged 65 years or older.

Methods: Demographics and medical information were extracted from electronic health records. Serum-fasting blood glucose was used to assess glycemic status. The association of hyperglycemia with the health outcomes was analyzed. A subset of patients aged 65 years or older was also analyzed.

Main Research Variables: Hyperglycemia, age, and health outcomes in patients with AML.

Findings: Forty patients experienced hyperglycemia during initial induction for AML. In the larger sample, no associations were noted between hyperglycemia and health outcomes. A significant relationship (p = 0.022) was noted between hyperglycemia and infection in patients aged 65 years or older. Patients aged 65 years or older had 5.6 times the risk of developing infection as those aged younger than 65 years. Although not statistically significant, patients aged 65 years or older with hyperglycemia had 2.5 more days of neutropenia and 1.5 days longer hospital length of stay.

Conclusions: This study provides preliminary evidence that hyperglycemia is prevalent during initial induction for AML and may have harmful consequences, particularly for patients aged 65 years or older. More research is needed to determine clinically significant levels of hyperglycemia and their impact on health outcomes.

Implications for Nursing: Oncology nurses can assess and proactively collaborate with members of the healthcare team to implement strategies to prevent or mitigate the harmful consequences of hyperglycemia.

cute myeloid leukemia (AML), a hematologic cancer, is the most common type of acute leukemia in adults, particularly among older adults (O'Donnell et al., 2012). The incidence of AML increases with age (Rodak, Fritsma, & Keohane, 2011), with the median age being 67 years at diagnosis (O'Donnell et al., 2012). The diagnosis and treatment of AML are associated with acuity and with symptom and side effect profile (O'Donnell et al., 2012). One side effect, hyperglycemia, has been shown to be detrimental in critical care and general medical-surgical patients (Richardson & Pollack, 2005), but is not well understood in patients with cancer.

Hyperglycemia, a disorder of glucose metabolism, is clinically defined as blood glucose of 126 mg/dl or greater (American Diabetes Association [ADA], 2015). Hyperglycemia is common in critical care and hospitalized patients, with about 32%